IT’S something we don’t miss until it’s gone – our hearing. When we start to lose things with old age, including our eyesight ...

New research reveals women who drink weekly sugary beverages face 5 times higher oral cancer risk. Learn the science behind ...

Novo Nordisk’s SOUL trial confirms that oral semaglutide significantly reduces the risk of heart attack, stroke, and cardiovascular death in people with type 2 diabetes and heart or kidney disease.

today announced initiation of its Phase 1 single- center clinical study of its lead therapeutic candidate, an oral transmucosal fast-acting high-dose aspirin formulation.

The cardiovascular safety of oral semaglutide, a glucagon-like peptide 1 receptor agonist, has been established in persons with type 2 diabetes and high cardiovascular risk. An assessment of the ...

Oral semaglutide reduced risk for cardiovascular events in people with type 2 diabetes, atherosclerotic CVD and kidney disease. It is now the first and only oral GLP-1 receptor agonist with proven ...

"The incidence of oral cavity cancer (OCC) is increasing among non-smokers and young individuals without traditional risk factors worldwide," write the researchers in their published paper. "In this ...

The risk for oral cavity cancer was over 4 to 5 times higher among women who consumed sugary drinks once or more a day. Still, the risk in this population was low, amounting to three cases per ...